1. Common clinic scenarios
'Doctor, my father is 72, has had diabetes for 20 years, and ophthalmology says he has diabetic retinopathy and has had a few laser treatments. Lately he's been forgetting things — even calling us by the wrong names. Is this related to the diabetic eye disease?'
'Doctor, I'm 58, diabetic for 8 years, last year's fundus exam was essentially normal. Recently I heard 'diabetes can cause dementia' — is that true? How much is my risk? Do I need any special workup?'
'Doctor, my mother is 80, diagnosed with mild dementia, also unsteady gait. She's never had a fundus exam — her doctor said «it doesn't matter at this point». But she's had diabetes for years. Do we really not need ophthalmology?'
All three scenarios revolve around the same theme: diabetes ⇄ retina ⇄ dementia. A May 2026 paper in American Journal of Ophthalmology (Khangura et al.) analysed 769,930 individuals ≥65 with an eye-exam record in the TriNetX global research network, stratifying for the first time by DR severity to answer: does more severe DR really correlate with higher dementia risk? This article distils it in clinic-friendly language.
2. Common patient Q&As
Q1: What are DR and dementia? Are they really linked?
A: Yes, with solid epidemiological linkage.
Diabetic retinopathy (DR) is microvascular damage from diabetes manifesting in the retina — microaneurysms, haemorrhages, exudates, neovascularisation. Clinically two stages: non-proliferative (NPDR) — early, with only microvascular abnormalities, and proliferative (PDR) — late, with fragile new vessels prone to vitreous haemorrhage and retinal detachment. DR is a leading cause of blindness in working-age adults.
Dementia is the umbrella term for chronic progressive cognitive decline affecting daily function. The most common types are Alzheimer's disease (AD) and vascular dementia (VD).
The link: diabetes itself elevates dementia risk (some authors even use the term type-3 diabetes), and DR is the most observable proxy for diabetic microvascular damage — if retinal vessels are damaged, cerebral vessels likely are too. Khangura 2026 (TriNetX) quantifies this association.
Diabetic retinopathy (DR) is microvascular damage from diabetes manifesting in the retina — microaneurysms, haemorrhages, exudates, neovascularisation. Clinically two stages: non-proliferative (NPDR) — early, with only microvascular abnormalities, and proliferative (PDR) — late, with fragile new vessels prone to vitreous haemorrhage and retinal detachment. DR is a leading cause of blindness in working-age adults.
Dementia is the umbrella term for chronic progressive cognitive decline affecting daily function. The most common types are Alzheimer's disease (AD) and vascular dementia (VD).
The link: diabetes itself elevates dementia risk (some authors even use the term type-3 diabetes), and DR is the most observable proxy for diabetic microvascular damage — if retinal vessels are damaged, cerebral vessels likely are too. Khangura 2026 (TriNetX) quantifies this association.
Q2: Why does diabetes raise dementia risk?
A: Research has proposed multiple shared pathways. (1) Hyperglycaemic neurotoxicity — long-term high glucose increases oxidative stress and reactive oxygen species (ROS), damaging neurons; (2) Insulin resistance and disrupted brain insulin signalling — the brain has its own insulin receptors; resistance interferes with neurotransmission and synaptic function; (3) Chronic inflammation — diabetes is a low-grade inflammatory state; inflammatory mediators cross the blood-brain barrier and cause neuroinflammation; (4) Microvascular damage — diabetes destroys small vessels throughout the body, the key mechanism behind vascular dementia; (5) Blood-brain barrier disruption — diabetes may accelerate BBB leakage. These mechanisms are not identical to Alzheimer's amyloid-plaque / tau pathology but share many pathological pathways.
Q3: Is "worse retina → higher dementia" truly causal?
A: The study confirms strong association, not direct causation. Khangura 2026 is a retrospective cohort, not a randomised trial, so it can show: "DR severity tracks stepwise with dementia incidence" and "the association persists after propensity-matching for age, sex, socioeconomic status, and comorbidities (hypertension, CKD, heart disease, depression, etc.)." Causation, however, requires other evidence. The mainstream interpretation: DR and cerebral small-vessel disease share microvascular pathology — DR is a visible proxy for systemic microvascular damage rather than a direct cause of dementia. In plain language: what you see in the fundus is a miniature of the invisible cerebral microvascular damage; severe retinopathy reflects a heavy systemic microvascular load, which is why it tracks with vascular dementia.
Q4: What are the dementia risks for PDR vs NPDR vs DM-no-DR?
A: Stepwise increase. Compared with non-diabetics, all-cause dementia HRs are: DM without DR 1.26, NPDR 1.41, PDR 1.58. So a diabetic person with DR has roughly a 41-58% higher dementia incidence than a non-diabetic, with severity tracking the magnitude. Within diabetes (vs DM without DR): NPDR HR 1.11 (+11%), PDR HR 1.20 (+20%); PDR vs NPDR 1.12 (+12% for all-cause). The standout figure: PDR's vascular-dementia HR is 2.08 — proliferative DR patients carry double the VD risk of non-diabetics.
Q5: Which dementia type is DR most strongly linked to?
A: Vascular dementia, by far the strongest. Effects of DR severity on the 3 dementia types:
• Vascular dementia (VD): PDR vs non-diabetic HR 2.08; NPDR 1.92; PDR vs NPDR 1.18. Clearly stepwise.
• All-cause dementia: PDR 1.58; NPDR 1.41; PDR vs NPDR 1.12. Also stepwise.
• Alzheimer's (AD): PDR vs non-diabetic 1.18 (marginal); NPDR vs non-diabetic 1.23; but PDR vs NPDR 0.93, PDR vs DM-no-DR 0.97 — neither significant. So AD risk is driven by diabetes itself, not DR severity.
Clinical meaning: DR represents vascular pathology, hence its strongest link to vascular dementia (essentially the same disease in different tissues — small-vessel occlusion). AD's core mechanism is amyloid and tau accumulation rather than microvascular damage, so DR severity has less leverage.
• Vascular dementia (VD): PDR vs non-diabetic HR 2.08; NPDR 1.92; PDR vs NPDR 1.18. Clearly stepwise.
• All-cause dementia: PDR 1.58; NPDR 1.41; PDR vs NPDR 1.12. Also stepwise.
• Alzheimer's (AD): PDR vs non-diabetic 1.18 (marginal); NPDR vs non-diabetic 1.23; but PDR vs NPDR 0.93, PDR vs DM-no-DR 0.97 — neither significant. So AD risk is driven by diabetes itself, not DR severity.
Clinical meaning: DR represents vascular pathology, hence its strongest link to vascular dementia (essentially the same disease in different tissues — small-vessel occlusion). AD's core mechanism is amyloid and tau accumulation rather than microvascular damage, so DR severity has less leverage.
Q6: I already have DR — am I going to get dementia? What should I do?
A: Elevated risk ≠ certainty. An HR of 1.58 means "58% higher incidence than baseline," not "a 58% chance of getting dementia." In Khangura 2026 with ~6.7 yr follow-up, PDR's actual all-cause dementia incidence was about 15.9% (vs 10.2% in non-diabetics). Most PDR patients did not develop dementia within 6-7 years.
What to do: (1) Glycaemic control — HbA1c < 7% (individualised by your metabolic doctor based on age and comorbidities); (2) Blood pressure — target < 130/80; (3) Smoking cessation, regular exercise, Mediterranean/DASH diet — good for both heart and brain; (4) Regular ophthalmology follow-up at the interval your ophthalmologist recommends; (5) Cognitive monitoring — if memory, judgement, language, or spatial function declines, see neurology / a dementia clinic early.
Treat DR as a warning light, not a verdict — a chance for earlier integrated care, not an unavoidable trajectory.
What to do: (1) Glycaemic control — HbA1c < 7% (individualised by your metabolic doctor based on age and comorbidities); (2) Blood pressure — target < 130/80; (3) Smoking cessation, regular exercise, Mediterranean/DASH diet — good for both heart and brain; (4) Regular ophthalmology follow-up at the interval your ophthalmologist recommends; (5) Cognitive monitoring — if memory, judgement, language, or spatial function declines, see neurology / a dementia clinic early.
Treat DR as a warning light, not a verdict — a chance for earlier integrated care, not an unavoidable trajectory.
Q7: When should diabetics start ophthalmology, and how often?
A: Get the first fundus exam at diabetes diagnosis; subsequent intervals individualised by your ophthalmologist. Per AAO / ADA international guidelines: at type-2 DM diagnosis, get a dilated fundus exam immediately (because DM is often long-standing before being diagnosed, with retinal damage potentially already present). Type-1 DM: first exam within 5 years of diagnosis. Subsequent follow-up: no DR every 1-2 years; NPDR every 6-12 months by severity; PDR or with macular edema every 3 months or less, with treatment considered.
In Taiwan, the diabetes shared-care network and many hospitals offer routine fundus screening for diabetics — discuss referral with your metabolic / family medicine physician. This article does not make claims about specific NHI programmes or fees; please check with your healthcare facility.
In Taiwan, the diabetes shared-care network and many hospitals offer routine fundus screening for diabetics — discuss referral with your metabolic / family medicine physician. This article does not make claims about specific NHI programmes or fees; please check with your healthcare facility.
3. Key takeaways: 8 things you really need to know
30-second takeaways
- Largest cohort: TriNetX 770K global analysis is the largest DR–dementia study to date
- Diabetes itself elevates dementia risk: HR 1.26 even without DR
- DR adds further risk: NPDR HR 1.41, PDR HR 1.58 — stepwise
- Vascular dementia is the most linked: PDR's VD HR = 2.08 — doubled risk
- AD link is weaker: AD risk driven by diabetes itself, no clear gradient by DR severity
- The eye is the brain's window: DR and cerebral small-vessel disease share microvascular pathology
- Elevated risk ≠ certainty: PDR's actual 6.7-yr incidence was 15.9%; most did not develop dementia
- Fundus exam has dual value: already standard diabetes care, now also an early dementia risk marker
4. DR basics: staging and epidemiology
Diabetic retinopathy is diabetic microvascular damage in the retina, classified by severity:
| Stage | Fundus findings | Clinical meaning |
|---|---|---|
| No DR | Normal fundus | Best status for diabetics, still 1-2 yr follow-up |
| Mild-moderate NPDR | Microaneurysms, dot/blot haemorrhages, hard exudates | Early signal; usually asymptomatic; follow-up every 6-12 mo |
| Severe NPDR | Extensive haemorrhages, venous beading, IRMA | On the verge of PDR; close 3-4 mo monitoring |
| Proliferative PDR | Neovascularisation, vitreous haemorrhage, fibrous proliferation, possible RD | High vision-loss risk; PRP laser, intravitreal injection, or surgery needed |
| With macular edema (DME) | Thickened macula, cystic spaces on OCT | Can occur at any DR stage; direct visual threat; excluded from this study to cleanly assess DR severity |
Epidemiology: DR is among the most common diabetic microvascular complications, with prevalence up to 26% in people with diabetes (US 2021), and ranks as the fifth leading cause of global blindness. Critically, fundus changes can develop while the patient feels nothing — which is why scheduled eye exams matter.
5. Dementia 3 main types: all-cause, AD, VD
Dementia denotes chronic, progressive cognitive decline that interferes with daily function. Three common types:
- Alzheimer's disease (AD): 60-70% of dementia, the most common. Core pathology: β-amyloid plaque and tau-tangle accumulation, neuronal death, hippocampal atrophy, progressive cognitive loss.
- Vascular dementia (VD): second most common. Core pathology: cerebral small-vessel occlusion, ischaemia, white-matter lesions, causing stepwise cognitive decline, often with gait disturbance and executive dysfunction. Directly linked to hypertension, diabetes, smoking, dyslipidaemia.
- All-cause dementia: composite epidemiological endpoint capturing every cause of dementia (the two above plus less common Lewy body, frontotemporal, mixed types) — reflects total dementia burden.
Bottom line: the strongest association in this study is DR severity → vascular dementia, fitting the pathological reality that both share small-vessel disease as the core mechanism.
6. What is the TriNetX 770K cohort study?
TriNetX is a global federated health research network covering 153 healthcare organisations and ~185 million de-identified patient records (diagnoses, procedures, medications, labs, imaging). Data refresh every 2-4 weeks; most institutions contribute 7-10 years of history. Khangura et al. 2026 design:
| Item | Detail |
|---|---|
| Inclusion | ≥ 65 yr, eye exam or OCT 2010-2020 |
| Exclusion | DME (excluded to avoid confounding since DME can occur at any DR stage) |
| Four cohorts | PDR (14,034), NPDR (29,188), T2DM without DR (208,640), non-diabetic (447,054) |
| Matching | 1:1 propensity score matching (greedy nearest neighbour). Variables: age, sex, SES, glaucoma, AMD, hypertension, CKD, stroke, MI, HF, depression |
| Follow-up | Mean 6.73 yr (SD 3.77) |
| Outcomes | Incidence of all-cause dementia, AD, VD; Cox proportional hazards; Kaplan-Meier curves |
This is the largest DR–dementia study to date — prior studies enrolled 3,000-4,000 patients; Khangura et al.'s DR cohort (43,222) is nearly 10× larger and the first capable of stratifying by DR severity.
7. The six key findings
| Finding | Key number | Clinical meaning |
|---|---|---|
| 1. Diabetes itself ↑ dementia risk | DM without DR vs non-DM: all-cause HR 1.26, AD 1.12, VD 1.38 (all p<0.0001) | Even with a normal fundus, diabetics need ongoing risk-factor control |
| 2. DR severity → stepwise ↑ dementia | NPDR HR 1.41, PDR HR 1.58 (vs non-DM) | Retinal severity mirrors systemic microvascular burden |
| 3. VD has the strongest link | PDR vs non-DM VD HR 2.08; NPDR 1.92; DM-no-DR 1.38 | Fundus = window to cerebral small-vessel disease — eye findings warn of brain risk |
| 4. AD doesn't track DR severity | PDR vs NPDR AD HR 0.93 (p = 0.31); PDR vs DM-no-DR 0.97 (p = 0.70) | AD is amyloid-driven not microvascular; diabetes itself raises AD, DR severity adds nothing further |
| 5. Mortality also rises stepwise | PDR vs non-DM mortality HR 2.14; NPDR 1.53; DM-no-DR 1.23 | Higher mortality may pre-empt AD onset in severe DR — possible survivorship bias underestimating AD link |
| 6. Methodological rigor | DME excluded; matching included glaucoma and AMD (both linked to dementia) | These controls reduce confounding from other eye diseases |
8. Why is ophthalmology an "early dementia risk marker"?
Anatomically and developmentally, the retina is an extension of the central nervous system — derived from neural ectoderm, containing neurons (retinal ganglion cells, bipolar cells, photoreceptors), myelinated nerve fibres (the optic nerve), and a CNS-like microvascular barrier (blood-retinal barrier). This makes the "the eye is the brain's window" metaphor biologically literal.
When diabetes damages microvasculature systemically, retinal and cerebral microvessels deteriorate in parallel: microaneurysms/haemorrhages/neovascularisation in the fundus correspond to lacunar infarcts, white-matter lesions, and microbleeds in the brain. The fundus is a miniature of the brain.
Khangura et al. also note their prior work showing that DR patients have higher plasma AD biomarkers (β-amyloid, tau, neurofilament light chain, GFAP) — suggesting DR may reflect not only vascular but also broader neurodegenerative processes. Although the present study found no significant DR-severity gradient for AD, this area remains active.
Clinical practical use: for diabetics, scheduled fundus exams are no longer "just eye care" — they are an opportunity for whole-body risk assessment. When ophthalmologists detect moderate-or-worse DR, they can flag systemic risk and prompt joint care with family medicine / metabolic / neurology — a low-cost, low-invasion, scalable model of early dementia risk-flagging.
9. Five things diabetics can do
💡 5 evidence-backed actions to cut both DR and dementia risk
- 1. Glycaemic control: HbA1c < 7% (individualised by your endocrinologist for age, comorbidities, hypoglycaemia risk). Long-term glycaemic variability worsens both DR and dementia risk.
- 2. Blood pressure: target < 130/80. Hypertension accelerates microvascular damage — a major driver of both DR progression and VD.
- 3. Quit smoking: smoking is an independent microvascular damaging factor, worsening DR and small-vessel dementia.
- 4. Regular exercise + Mediterranean / DASH diet: 150 min/wk moderate aerobic + high-fibre, omega-3-rich, low-refined-sugar eating benefits both cardiovascular and cognitive function.
- 5. Regular fundus follow-up + cognitive awareness: per international guidelines (6 mo to 2 yr by severity); family members should monitor for changes in memory, judgement, spatial sense, and seek early evaluation.
10. Visual red flags for diabetics — when to go in immediately
Even if you follow regular check-ups, see ophthalmology same-day for any of the following:
🚨 Diabetic visual red flags
- Sudden visual decline (one or both eyes, any degree)
- Sudden floaters or dark shadows — possible vitreous haemorrhage (PDR progression)
- Visual field defect (curtain over part of vision) — possible retinal detachment
- Distorted vision (straight lines bent, sizes changing) — possible macular edema progression
- Acute eye pain + blurred vision + nausea — neovascular glaucoma, a serious PDR complication
If any of the above, go to ophthalmology ER or general ER the same day.
11. Taiwan context and NHI notes
⚠️ This section strictly follows "no source — no claim"
- Diabetic fundus exam: a routine ophthalmic exam; Taiwan's diabetes shared-care network and most hospitals offer scheduled fundus screening for diabetics. Specific procedures, intervals, and coverage vary by facility and current NHI policy — check with your provider and the NHIA portal.
- OCT (optical coherence tomography): the key tool for diagnosing diabetic macular edema; available at most facilities. NHI coverage depends on indication and physician judgement.
- DR treatment (intravitreal anti-VEGF, laser, vitrectomy): outside the scope of this article, which focuses on the DR–dementia association. A separate article in this series will cover treatment-related coverage.
- Dementia diagnosis and medication: this article makes no claims about cognitive workup, neuroimaging, or pharmacotherapy (e.g., donepezil, memantine). Please see neurology / a dementia clinic.
12. Conclusion: fundus exams are a two-birds-one-stone health investment
Khangura et al.'s 2026 TriNetX 770K cohort delivers three key messages:
- Diabetes itself is an independent dementia risk factor, +26% even with a normal fundus (shared pathological pathways)
- DR severity → dementia (especially VD) risk rises stepwise; the fundus marks systemic microvascular burden
- Regular fundus exam = dual value: standard diabetes care + early dementia risk marker enabling integrated care
The most important take-home for diabetics: don't wait until your eyes or mind feel «off». The best protection for ophthalmic and cognitive health remains solid glycaemic and BP control + lifestyle + scheduled eye exams — the most cost-effective investment for heart, brain, and eyes alike.
📚 HsiaoEye Related Articles
- 6 Floater Red Flags — Vitreous haemorrhage from DR often presents as new floaters
- Glaucoma — Patient Education — PDR can lead to neovascular glaucoma
- Ophthalmic Trauma — Overlooked Burden — Public-health angle on eye health red flags
- Recurrent SK After HZO — Another chronic eye condition needing ongoing follow-up
References
- Khangura MS, Spratt MA, Gao A, Manhapra A, Siegel NH, Chen X, Poulaki V, Ness S, Stein T, Subramanian ML. The Association Between Diabetic Retinopathy Severity and Dementia Risk: A TriNetX Longitudinal Cohort Study. Am J Ophthalmol. 2026;285:300–309. doi:10.1016/j.ajo.2026.02.014.
- Fang M, Hu J, Weiss J, et al. Lifetime risk and projected burden of dementia. Nat Med. 2025;31(3):772–776.
- Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604.
- Chai YH, Han YP, Zhang JY, Zhou JB. Diabetic retinopathy and brain structure, cognition function, and dementia: a bidirectional mendelian randomization study. J Alzheimer's Dis. 2024;97(3).
- Lee CS, Krakauer C, Su YR, et al. Diabetic Retinopathy and Dementia Association, beyond diabetes severity. Am J Ophthalmol. 2023;249:202–211.
- Pedersen FN, Stokholm L, Pouwer F, et al. Diabetic retinopathy predicts risk of Alzheimer's Disease: a Danish registry-based nationwide cohort study. J Alzheimer's Dis. 2022;86(1).
- Hwang PH, Longstreth WT, Thielke SM, et al. Ophthalmic conditions associated with dementia risk: the cardiovascular health study. Alzheimer's Dementia. 2021;17(9).
- Exalto LG, Biessels GJ, Karter AJ, Huang ES, Quesenberry CP, Whitmer RA. Severe diabetic retinal disease and dementia risk in type 2 diabetes. J Alzheimer's Dis. 2014;42 Suppl 3:S109–117.
- Cheng D, Zhao X, Yang S, Wang G, Ning G. Association between diabetic retinopathy and cognitive impairment: a systematic review and meta-analysis. Front Aging Neurosci. 2021;13:692911.
- Lundeen EA, Burke-Conte Z, Rein DB, et al. Prevalence of diabetic retinopathy in the US in 2021. JAMA Ophthalmol. 2023;141(8).
- Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020. Lancet Glob Health. 2017;5(12):e1221–e1234.
- Mutlu U, Colijn JM, Ikram MA, et al. Association of retinal neurodegeneration on optical coherence tomography with dementia: a population-based study. JAMA Neurol. 2018;75(10):1256–1263.
- Little K, Llorián-Salvador M, Scullion S, et al. Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends Endocrinol Metab. 2022;33(1):50–62.
- Subramanian ML, Sampani K, Ness S, et al. Biomarkers for Alzheimer's disease are upregulated in patients with diabetic retinopathy. J Alzheimer's Dis. 2025.
- de la Monte SM. The full spectrum of Alzheimer's disease is rooted in metabolic derangements that drive type 3 diabetes. Adv Exp Med Biol. 2019;1128:45–83.
- Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA. 2010;303(3):267–268.
Frequently asked questions
Does more severe diabetic retinopathy really mean higher dementia risk?
Per the 2026 Khangura TriNetX cohort of 769,930 people, compared with non-diabetics the all-cause dementia hazard ratio rose stepwise: about 1.26 for diabetes without retinopathy, 1.41 for NPDR and 1.58 for proliferative DR. This is a statistical association, not certainty that DR causes dementia.
Which type of dementia is diabetic retinopathy most strongly linked to?
Vascular dementia, by far. Proliferative DR carried a vascular-dementia hazard ratio of about 2.08 versus non-diabetics, roughly doubling the risk. Alzheimer's risk, in contrast, was driven by diabetes itself with no clear gradient by DR severity, since its core mechanism is amyloid and tau rather than microvascular damage.
Why can a fundus exam serve as an early dementia risk marker?
Because retinal microvascular damage and cerebral small-vessel disease share the same pathology — hyperglycaemia, chronic inflammation and oxidative stress — so the eye is regarded as the brain's window. What is seen in the fundus is a miniature of invisible cerebral small-vessel disease; more severe retinopathy reflects a heavier systemic microvascular burden and higher vascular-dementia risk.
I already have diabetic retinopathy — does that mean I will definitely get dementia?
Elevated risk is not certainty. A hazard ratio of 1.58 means about 58% higher incidence than baseline, not a 58% chance of dementia. Over roughly 6.7 years of follow-up, the actual all-cause dementia incidence in the proliferative-DR group was about 15.9% (versus 10.2% in non-diabetics), so most patients did not develop dementia. Treat DR as a warning light prompting integrated care.
When should people with diabetes start eye exams and how often?
Per international guidelines, type-2 diabetes warrants a dilated fundus exam at diagnosis because diabetes is often long-standing before detection; type-1 diabetes warrants a first exam within five years. Intervals are then individualised by your ophthalmologist: every 1-2 years with no DR, every 6-12 months for NPDR by severity, and within 3 months with closer monitoring and possible treatment for PDR or macular edema.
What can people with diabetes do to lower both retinopathy and dementia risk?
The article lists five evidence-backed actions: control blood sugar (HbA1c target under 7%, individualised by your metabolic doctor); control blood pressure (target below 130/80); quit smoking; exercise regularly with a Mediterranean or DASH diet; and keep regular fundus follow-up while watching for changes in memory, judgement and spatial sense, seeking early evaluation. These benefit the heart, brain and eyes alike.